JNJ 87704916
Alternative Names: JNJ-4916; JNJ-87704916Latest Information Update: 14 Apr 2024
At a glance
- Originator Johnson & Johnson Innovation
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Combination therapy) in USA (Intratumoural) (NCT06311578)
- 28 Mar 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (Intratumoural) (NCT06311578)
- 19 Mar 2024 Preclinical trials in Solid tumours in USA (Intratumoural), prior to March 2024 (NCT06311578)